Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-lb-c12
Abstract: Background: DZB is an oral small-molecule Fibroblast Growth Factor Receptor 1/2/3 inhibitor (FGFRi) with clinically relevant activity in FGFR2-fusion cholangiocarcinoma. Extensive kinase profiling identified Colony-Stimulating Factor 1 receptor (CSF1R) as an additional anti-cancer target for… read more here.
Keywords: urothelial cancer; fgfr; csf1r; csf1r inhibitor ... See more keywords
Auditory Brainstem Deficits from Early Treatment with a CSF1R Inhibitor Largely Recover with Microglial Repopulation
Sign Up to like & getrecommendations! Published in 2021 at "eNeuro"
DOI: 10.1523/eneuro.0318-20.2021
Abstract: Abstract Signaling between neurons and glia is necessary for the formation of functional neural circuits. A role for microglia in the maturation of connections in the medial nucleus of the trapezoid body (MNTB) was previously… read more here.
Keywords: csf1r inhibitor; microglial repopulation; auditory brainstem; treatment ... See more keywords
An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Nuclear Medicine"
DOI: 10.2967/jnumed.119.230466
Abstract: The immune function within the tumor microenvironment has become a prominent therapeutic target, with tumor-associated macrophages (TAMs) playing a critical role in immune suppression. We propose an 89Zr-labeled high-density lipoprotein (89Zr-HDL) nanotracer as a means… read more here.
Keywords: response; csf1r inhibitor; hdl; 89zr hdl ... See more keywords